Similarly, studies show that IL6-induced chemoresistance is developed by cross-talk of MAPK/ERK and NFκB signaling; thus, upstream blockage of these pathways can potentiate the anti-tumor response of anti-IL6 and anti-IL6R antibodies [205]. Here, NFKB1 is linked to neoplasm.